1. Scrip
  2. >>R&D
  3. >>Clinical Trials

89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients

 
• By Joseph Haas

At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.

Cirrhotic liver
89bio's pegozafermin shows fibrosis reduction in small subgroup of cirrhotic NASH patients • Source: Shutterstock

Perhaps already best positioned in the competitive FGF21 analog class in non-alcoholic steatohepatitis development, 89bio, Inc. bolstered its positioning with a late-breaker presentation on 12 November at the American Association for the Study of Liver Disease meeting with subgroup analysis from its successful Phase IIb study of pegozafermin showing that the weekly injectable drug might offer fibrosis benefit in the sickest patients, those with cirrhosis (F4 fibrosis).

Key Takeaways

  • 89bio presented Phase IIb subgroup analysis at the AASLD conference suggesting a fibrosis-reduction benefit for pegozafermin in cirrhotic NASH patients.

89bio is competing primarily with Akero Therapeutics, Inc. and its Phase II efruxifermin and privately held Boston Pharmaceuticals...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Genmab Looks To Keep Ahead Of Lilly In Folate ADCs

 
• By Andrew McConaghie

The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

More from R&D

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.